NCT02474810

Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol

Comparison of an Intensive Versus a Standard Hemodialysis Central Venous Catheter Dysfunction Protocol Using Alteplase

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Nova Scotia Health Authority · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Central venous catheters (CVCs) are used for vascular access by approximately 56% of our 380 hemodialysis (HD) patients at the Capital Health Renal Program. The major complication of these catheters includes thrombosis and infection. Catheter locking solutions such as recombinant tissue plasminogen activator (rt-PA), Alteplase (Cathflo®) are used to treat and prevent clotting of the catheter during HD treatments and during the interdialytic period. Evidence to guide the use of rt-PA is limited. This quality assurance project will compare the effectiveness and cost of an intensive versus a standard catheter dysfunction protocol for rt-PA in HD patients.

Detailed description

The proposed study will be a retrospective cohort study of consecutive HD patients conducted at a HD unit using two catheter dysfunction protocols during January 2013 to Septebmer 2013. In the Intensive Protocol, rt-PA intervention is administered to all catheters based on blood flow and/or line reversal. In the Standard Protocol, rt-PA intervention is administered to all catheters based only on blood flow.

Conditions

• Chronic Renal Insufficiency

Interventions

Type	Name	Description
DRUG	Alteplase	Alteplase for CVC dysfunction.

Timeline

• Start date: 2013-01-01
• Primary completion: 2015-07-01
• Completion: 2015-09-01
• First posted: 2015-06-18
• Last updated: 2024-08-21

Locations

1 site across 1 country: Canada